

MONOCLONAL ANTIBODY DATASHEET



Clone F18 P3 B6 against human CYP3A5

Product Description	Monoclonal antibody directed against human CYP3A5. Does not cross-react with CYP3A4 or CYP3A7 (see below). Supplied as hybridoma supernatant (unpurified).
Storage	Store at -20°C . Avoid repeated freeze-thaw cycles.
Intended Use	For laboratory (research) purposes only.
Isotype	IgG1, k
Clone	F18 P3 B6
Immunogen	Ovalbumin-conjugated synthetic peptide; DSRDGTLSGE (C-terminal sequence)
B Cell Donor	BALB-c mouse
Fusion Partner	Ag 8563
Positive Control	IHC: formalin-fixed, paraffin-embedded squamous oesophagus cancer sections. Western blot: recombinant CYP (shown below @ 0.5 pmol per lane). Negative control: Gentest Cat. No. M101b.
Significance	This monoclonal antibody (MAb), when used in conjunction with the MAb specific to CYP3A7 (clone F19 P2 H2), is able to differentiate between the CYP family 3 members CYP3A5 and CYP3A7.

Applications		Recommended Usage Conditions (conditions should be optimised by the user)
ELISA	✓	Undiluted (titre: 1/16)
Western blot	✓	1/10 dilution
IHC	✓	1/5 dilution, antigen retrieval: microwave 20 min @ 800W in 10 mM citrate buffer, pH 6.0

Clinical significance	Results observed
Colorectal cancer	- CYP3A5 showed a significantly greater intensity of immunohistochemical staining in tumour samples compared with normal colon. There was a correlation between CYP3A5 expression and tumour stage.
Ovarian cancer	- CYP3A5 showed a significantly greater intensity of immunohistochemical staining in tumour samples compared with normal ovary.
Breast cancer	- CYP3A5 showed significant correlation with oestrogen receptor in breast cancer.

References	<p>Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S, Murray GI (2005). Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. <i>Clin Cancer Res.</i> 11: 3758-3765.</p> <p>Downie D, McFadyen MCE, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT, Murray GI (2005) Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers. <i>Clin Cancer Res.</i> 11: 7369-7375.</p> <p>Murray G I, Patimalla S, Stewart K N, Miller I D & Heys S D (2010) Profiling the expression of cytochrome P450 in breast cancer. <i>Histopathology.</i> 57: 202-211.</p>
-------------------	--

ELISA TEST						
3A5	2B6	2R1	2U1	4F11	26A1	2A(6/7/13)
+	-	-	-	-	-	-
Reactivity with BSA-conjugated synthetic C-terminus region derived from CYP proteins						

WESTERN BLOT						
1A2	1B1	2A6	2B6	2C8	2C9	2E1
-	-	-	-	-	-	-
Reactivity with recombinant CYP proteins. Positive control: CYP3A5						

